The latest progress of personalized drug screening and therapy research for common clinical tumors through the PDX model platform.
10.1016/j.jpha.2025.101225
- Author:
Yitong YUAN
1
;
Hongling GAO
2
;
Yanhong LI
3
;
Xiangying JIAO
4
Author Information
1. Laboratory Animal Center, Shanxi Key Laboratory of Experimental Animal Science and Human Disease Animal Model, Shanxi Medical University, Taiyuan, 030001, China.
2. Department of Pathology, Qinghai Provincial People's Hospital, Xining, 810007, China.
3. NHC Key Laboratory of Comparative Medicine, National Human Diseases Animal Model Resource Center, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, National Center of Technology Innovation for animal Model, Institute of Medical Laboratory Animal Science, CAMS & PUMC, Beijing, 100021, China.
4. Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Key Laboratory of Cellular Physiology of Shanxi Province, The Department of Physiology, Shanxi Medical University, Taiyuan, 030001, China.
- Publication Type:Review
- Keywords:
Common clinical tumors;
PDX model database;
Patient-derived xenograft;
Personalized medicine;
Targeted drug screening
- From:
Journal of Pharmaceutical Analysis
2025;15(10):101225-101225
- CountryChina
- Language:English
-
Abstract:
The establishment of mouse models is critical for discovering the biological targets of tumorigenesis and cancer development, preclinical trials of targeted drugs, and formulation of personalized therapeutic regimens. Currently, the patient-derived xenograft (PDX) model is considered a reliable animal tumor model because of its ability to retain the characteristics of the primary tumor at the histopathological, molecular, and genetic levels, and to preserve the tumor microenvironment. The application of the PDX model has promoted in-depth research on tumors in recent years, focusing on drug development, tumor target discovery, and precise treatment of patients. However, there are still some common questions. This review introduces the latest research progress and common questions regarding tumors with high mortality rates, focusing on their application in targeted drug screening and the formulation of personalized medical strategies. The challenges faced, improvement methods, and future development of the PDX model in tumor treatment applications are also discussed. This article provides technical guidance and comprehensive expectations for anti-cancer drug screening and clinical personalized therapy.
